Tag Archive for: Haleon

The company beat market estimates for fourth-quarter results today, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the benefits of its consumer health unit spin-off.

The British drugmaker said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines.

British drugmaker GSK on Friday said it raised 885.6 million pounds ($1.08 billion) from a discounted stake sale in Haleon, cutting its shareholding to 7.4% in the world’s largest standalone consumer healthcare firm.

GSK agreed to settle a U.S. lawsuit alleging its discontinued heartburn drug Zantac caused cancer, the British drugmaker said on Friday, preventing the first such case from going to trial next month.

British drugmaker GSK on Friday sold 240 million shares in its consumer healthcare business Haleon at 335 pence per share, raising about 804 million pounds ($1 billion), the company said.

The company’s CFO said Pfizer has long been clear about its intention to sell off the stake, suggesting that the reason the potential of the selloff has gained traction is because the selling window opens around the time that Haleon’s results are announced.

GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory medicines.

Haleon, carved out of British drugmaker last July in the biggest listing in Europe for more than a decade, is the world’s biggest standalone consumer health business selling non-prescription drugs, vitamins and oral care products.

The FDA issued complete response letters to Phathom Pharmaceuticals, flagging the presence of N-nitroso-vonoprazan (NVP) impurities detected in the company’s approved Helicobacter pylori drug products, the company announced Thursday.

GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and unveiled an upbeat forecast for 2023.